NATR · XBRL financial data

Nature's Sunshine Products financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NATR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	385,205	444,084	421,910	445,320	454,364	480,144
Cost of goods and services sold	101,276	115,467	122,150	124,193	129,676	132,420
Gross profit	283,929	328,617	299,760	321,127	324,688	347,724
Research and development	1,500	1,400	1,500	1,600	1,700	1,900
Selling, general and administrative	131,297	154,103	153,125	167,058	164,004	178,390
Operating income (loss)	21,482	34,670	16,258	18,749	20,095	24,743
Interest expense	102	250	249	69	146	98
Other income (expense)	1,339	(2,848)	(1,043)	1,453	(1,669)	5,069
Income tax expense (benefit)	(137)	1,615	14,665	3,786	10,534	9,361
Net income (loss)	—	—	(390)	15,076	7,696	19,521
Earnings per share, basic USD per share	1.09	1.45	(0.02)	0.79	0.41	1.08
Earnings per share, diluted USD per share	1.07	1.42	(0.02)	0.77	0.40	1.06
Weighted average shares, basic thousands of shares	19,537	19,858	19,326	19,066	18,616	18,005
Weighted average shares, diluted thousands of shares	19,968	20,327	19,326	19,466	19,089	18,468

Fiscal years (NATR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	92,069	86,184	60,032	82,373	84,700	93,891
Accounts receivable	7,375	8,871	14,106	8,827	9,477	8,602
Inventory	47,683	60,852	67,949	66,895	59,443	68,312
Prepaid and other current assets	6,938	8,760	7,420	7,722	6,959	8,040
Total current assets	154,065	164,667	149,507	165,817	160,579	178,845
Property and equipment, net	54,355	50,857	46,162	45,000	39,585	32,915
Right-of-use asset	20,210	18,349	16,145	13,361	12,799	17,600
Total assets	249,498	258,874	229,778	249,773	240,855	261,146
Accounts payable	6,486	9,702	6,349	7,910	8,912	8,021
Accrued liabilities	31,710	31,600	25,591	33,162	25,399	34,080
Current portion of long-term debt	1,306	1,244	1,174	0	—	—
Total current liabilities	69,654	76,670	65,582	76,753	65,692	78,538
Long-term debt	2,418	1,174	0	—	—	—
Lease liability, non-current	16,412	15,919	13,745	10,376	10,277	15,630
Total liabilities	92,264	97,470	82,731	90,233	79,864	99,593
Retained earnings	26,030	35,025	34,635	49,711	57,407	76,928
Total liabilities and equity	249,498	258,874	229,778	249,773	240,855	261,146
Common shares outstanding (cover page) thousands of shares	19,796	19,449	19,056	18,819	18,484	17,508

Fiscal years (NATR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	—	(390)	15,076	7,696	19,521
Stock-based compensation	3,787	3,731	2,901	4,893	4,788	5,780
Depreciation and amortization	10,743	11,162	11,025	11,816	14,219	13,844
Net cash from operating activities	37,659	34,608	710	41,226	25,298	35,321
Purchases of property and equipment	4,905	6,666	7,628	10,478	10,971	6,480
Net cash from investing activities	(4,905)	(6,612)	(7,628)	(10,478)	(10,971)	(6,480)
Share repurchases	0	7,425	13,571	6,397	8,859	16,309
Dividends paid	0	19,858	0	—	—	—
Net cash from financing activities	3,878	(31,721)	(16,246)	(7,956)	(9,905)	(23,773)
Net change in cash	38,440	(5,885)	(26,152)	22,341	2,327	9,191

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Natures Sunshine Products	89,377	116,603	not reported	17.3M	—	Q3 FY26 10-QSep 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Tvardi Therapeutics	15,765	not reported	(9,228)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72,054	0	1,518*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Rezolute	10,615	not reported	(13,146)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
SELLAS Life Sciences Group	138,343	not reported	(7,588)*	201.9M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Precigen	14,959	74,148	not reported	358.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.